(-)-trans-3-(5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidin-2,5-dione,
ARQ 197,
ARQ-197,
ARQ197,
tivantinib,
Tivantinib,
905854-02-6,
ARQ-197,
ARQ 197,
ARQ197,
Tivantinib (ARQ 197),
(3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione,
UNII-PJ4H73IL17,
PJ4H73IL17,
(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione,
1000873-98-2,
905853-99-8,
Tivantinib [USAN:INN],
Tivantinib; ARQ197,
ARQ 197, Tivantinib,
ARQ 197 (Tivantinib),
Tivantinib (ARQ-197),
cc-86,
SCHEMBL44944,
Tivantinib (JAN/USAN/INN),
GTPL7948,
CHEMBL2103882,
CHEBI:91398,
QCR-102,
UCEQXRCJXIVODC-PMACEKPBSA-N,
ARQ-197,Tivantinib, ARQ197,
ARQ197; ARQ-197;Tivantinib,
BCPP000042,
Tivantinib; 905854-02-6,
AOB87130,
BCP02529,
EX-A2169,
KS-00001DU5,
rel-(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione,
CAS:905854-02-6;Tivantinib,
BDBM50146168,
s2753,
AKOS022182739,
ZINC100016063,
API0024737,
DB12200,
RL05700,
SB16527,
(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione,
AC-25009,
AJ-89918,
AS-16991,
BC638836,
EN002686,
HY-50686,
SC-86236,
J3.496.311H,
D10173,
W-5506,
J-501255,
BRD-K33379087-001-01-8,
(3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoli,
(+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1H-indol-3-yl)pyrrolidine-2,5-dione,
(+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2,5-dione,
(+/-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione,
(_)-trans-3-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl)-4(1h-indol-3-yl)pyrrolidine-2,5-dione,
(3R,4R)-3-(2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione,
(3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione,
(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-yl)-4-(1H-indole-3-yl)pyrrolidine-2,5-dione,
2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-,
2,5-Pyrrolidinedione,3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-,(3R,4R)-rel-,
TIV,
trans 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione,
Tivantinib [INN],
D0ZI1F,
3- -4- -pyrrolidine-2,5-dione,
CS-0030,
CID11494412,
CID 11494412,
A11087,
C551661,
1-[(3r,4r)-4-(1h-Indol-3-Yl)-2,5-Dioxopyrrolidin-3-Yl]pyrrolo[3,2,1-Ij]quinolinium,
(-)-trans-3-(5,6-dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidin-2,5-dione,
2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-rel-,
3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione,
M97,